Yang Zhonghui, Zhang Guang, Wu Qiaowei, Zhu Yujing, Xu Shancai, Shi Huaizhang
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Front Surg. 2025 Apr 22;12:1536912. doi: 10.3389/fsurg.2025.1536912. eCollection 2025.
Tandem occlusion is a significant risk factor for poor outcomes following intravenous thrombolysis. The necessity of bridging therapy [intravenous thrombolysis prior to mechanical thrombectomy (MT)] for patients with tandem occlusion remains controversial. This study assessed the safety and efficacy of direct MT vs. bridging therapy in patients with tandem occlusions in the anterior circulation.
This retrospective study enrolled patients with anterior circulation tandem occlusions treated with either direct mechanical thrombectomy (MT-alone group) or intravenous alteplase thrombolysis followed by MT (bridging group) between January 2019 and March 2022. The primary outcome was prespecified as a favorable outcome [modified Rankin Scale (mRS) score of 0-2] at 90 days. Secondary outcomes included successful reperfusion, overall mortality at 90 days, and rates of symptomatic intracranial hemorrhage (SICH) and asymptomatic intracranial hemorrhage (aSICH).
A total of 110 patients were enrolled, with 49 in the MT-alone group and 61 in the bridging group. A favorable outcome (mRS score of 0-2) at 90 days was achieved in 25 patients (51.0%) in the MT-alone group and in 34 patients (55.7%) in the bridging group, showing no significant difference between the groups, with an adjusted odds ratio (aOR) of 1.17 (95% CI, 0.47-2.90; = 0.743). The incidence of aSICH was higher in the bridging group than in the MT-alone group [31.1% vs. 14.3%; aOR, 2.86 (95% CI, 1.04-7.88); = 0.042]. Rates of successful reperfusion, overall mortality at 90 days, and SICH were similar between the groups. Multivariate analysis showed that a lower baseline National Institutes of Health Stroke Scale (NIHSS) score ( = 0.005), intraprocedural tirofiban administration ( = 0.012), and internal carotid artery stent implantation ( = 0.040) were associated with a favorable outcome at 90 days.
This study found no evidence that prior intravenous thrombolysis affects clinical or imaging outcomes in patients with acute ischemic stroke due to anterior circulation tandem occlusions after endovascular thrombectomy. Bridging therapy may be associated with an increased rate of aSICH. Intraprocedural tirofiban administration, stent implantation, and a lower baseline NIHSS score were associated with favorable outcomes.
串联闭塞是静脉溶栓后预后不良的重要危险因素。对于串联闭塞患者,桥接治疗(机械取栓术前静脉溶栓)的必要性仍存在争议。本研究评估了直接机械取栓与桥接治疗在前循环串联闭塞患者中的安全性和有效性。
本回顾性研究纳入了2019年1月至2022年3月期间接受直接机械取栓(单纯机械取栓组)或静脉注射阿替普酶溶栓后再行机械取栓(桥接组)治疗的前循环串联闭塞患者。主要结局预先设定为90天时的良好结局(改良Rankin量表评分0 - 2分)。次要结局包括成功再灌注、90天总体死亡率、症状性颅内出血(SICH)和无症状性颅内出血(aSICH)发生率。
共纳入110例患者,单纯机械取栓组49例,桥接组61例。单纯机械取栓组25例患者(51.0%)在90天时达到良好结局(改良Rankin量表评分0 - 2分),桥接组34例患者(55.7%)达到良好结局,两组之间无显著差异,调整后的优势比(aOR)为1.17(95%CI,0.47 - 2.90;P = 0.743)。桥接组aSICH发生率高于单纯机械取栓组[31.1%对14.3%;aOR,2.86(95%CI,1.04 - 7.88);P = 0.042]。两组之间成功再灌注率、90天总体死亡率和SICH发生率相似。多因素分析显示,较低的基线美国国立卫生研究院卒中量表(NIHSS)评分(P = 0.005)、术中使用替罗非班(P = 0.012)和颈内动脉支架植入(P = 0.040)与90天时的良好结局相关。
本研究未发现证据表明血管内取栓术后,预先静脉溶栓会影响前循环串联闭塞所致急性缺血性卒中患者的临床或影像学结局。桥接治疗可能与aSICH发生率增加有关。术中使用替罗非班、支架植入以及较低的基线NIHSS评分与良好结局相关。